Dear Sir, A lively controversy has been focused on the possible existence of two distinct types of islet cell antibodies (ICA) [1] [2] [3] . One type of antibody is thought to be "whole" or "non-restricted", reacting with whole islet cells and predictive of subsequent progression to insulindependent diabetes mellitus in a high-risk population [1, 2] . The other type of antibody is thought to be "selective" or "restricted", raised against the beta cell and poorly associated with subsequent progression to insulin-dependent diabetes. Sera containing "restricted" antibodies gave a granular immunofluorescence pattern [3] . The high-risk population in these reports included patients with ICA-positive non-diabetic endocrine autoimmune syndrome [1] and the first-degree relatives of insulin-dependent diabetic patients [2] .
patient in the non-progression group, showed "whole" or "non-restricted" ICA reacting with whole islet cells. Two samples from a patient treated with sulphonylurea showed a "restricted" or "selective" pattern of reaction only with beta cells. However, the reactivity to beta cells was abolished after absorption of the serum with human insulin-coated sepharose 4B beads. This suggests that the "restricted" pattern was related to the presence of insulin autoantibodies (IAA). The false-positive effect of a high titre of IAA on the ICA assay has already been reported [6] .
The present study demonstrated that classical "whole" or "nonrestricted" type ICA was detected in non-progressive as well as slowly progressive ICA-positive non-insulin-dependent diabetic patients. The presence of heterogeneous ICA and the clinical value of subclassifying ICA for assessing the risk of progressive beta-cell damage was not confirmed in this study.
Yours sincerely, T. Kobayashi, K. Nakanishi, T. Murase and K. Kosaka
